B-RAF is a target for melanoma treatments. Which of the following best describes therapeutic approaches targeting the B-RAF pathway?

Question

Answer

Vemurafenib, dabrafenib and trametinib are reversible inhibitors of the kinase domain of B-RAF

Answer

Vemurafenib blocks MAPK signalling by wild-type B-RAF, B-RAF(V600E) mutant and p61 B-RAF (V600E) mutant to induce cell cycle arrest and apoptosis of melanocytes

Answer

Vemurafenib blocks MAPK signalling by B-RAF(V600E) mutant, to induce cell cycle arrest and apoptosis of melanocytes

Answer

Vemurafenib, dabrafenib and trametinib are non-competitive inhibitors of the kinase domain of B-RAF

Crowdly

B-RAF is a target for melanoma treatments. Which of the following best describes...

Want instant access to all verified answers on learning.monash.edu?